Obinutuzumab in untreated primary membranous nephropathy: An observational case series
Nephrology · 2024-11 · 29 (11) · 709-716
DOI: 10.1111/nep.14331 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nephrology, online erschienen am 03.06.2024. Verfasst von Jinling Hao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Taiyuan Hospital of Peking University First Hospital, Taiyuan, Shanxi, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Antibodies, Monoclonal, Humanized, Remission Induction, Receptors, Phospholipase A2. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
As an initial treatment for primary membranous nephropathy (PMN), there remains a significant proportion of patients for whom rituximab is not fully effective. Here, we aimed to assess the effectiveness and safety of obinutuzumab as initial treatment in patients with PMN.
Methods
In this observational case series, patients diagnosed with PMN and treated with obinutuzumab as initial treatment were included. Treatment response was assessed by 24‐h urine total protein (24 h UTP) and serum albumin, and immunologic remission was assessed by phospholipase A2 receptor (PLA2R) antibodies.
Results
Twelve patients with PMN receiving obinutuzumab as initial treatment were included. Over 6 months, a statistically significant reduction in 24 h UTP levels ( p = 0.003) and an increase in serum albumin levels were observed ( p < 0.001). By the 6‐month follow‐up, two patients (16.7%) achieved complete remission, eight (66.6%) reached partial remission, and two (16.7%) showed no remission. Immunological remission was observed in 44.4% of evaluable patients ( n = 9) after 3 months, increasing to 100% (6/6) at 6 months. Except for cases 1, 2, and 3, the total B cell counts in the remaining patients fell to less than 5 cells/μL before the administration of the second dose of obinutuzumab, including seven patients with counts as low as 0 cells/μL. Mild to moderate treatment‐related adverse events (TRAEs) were reported in 58.3% (7/12) of the patients. No serious TRAEs were reported.
Conclusions
Obinutuzumab demonstrates promising potential as an initial treatment for PMN, with good effectiveness and a manageable safety profile. Further large‐scale prospective studies are needed to confirm these findings. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Taiyuan Hospital of Peking University First Hospital, Taiyuan, Shanxi, China.
- Department of Nutrition, Taiyuan Hospital of Peking University First Hospital, Taiyuan, Shanxi, China.
- Department of Nephrology, Peking University First Hospital, Beijing, China.
ORCID-Profile: Jinling Hao
Zitieren
APA
Hao, J., Wang, J., Zhou, P., Xu, R., & Chen, X. (2024). Obinutuzumab in untreated primary membranous nephropathy: An observational case series. Nephrology, 29(11), 709-716. https://doi.org/10.1111/nep.14331
Vancouver
Hao J, Wang J, Zhou P, Xu R, Chen X. Obinutuzumab in untreated primary membranous nephropathy: An observational case series. Nephrology. 2024;29(11):709-716. doi:10.1111/nep.14331
BibTeX
@article{Hao2024,
author = {Hao, Jinling and Wang, Jing and Zhou, Pan and Xu, Rong and Chen, Xiaoli},
title = {Obinutuzumab in untreated primary membranous nephropathy: An observational case series},
journal = {Nephrology},
year = {2024},
volume = {29},
number = {11},
pages = {709--716},
doi = {10.1111/nep.14331}
}
EUVIMED